Carving your way through the resistance minefield
2006-10-26 - English

Facing An Epidemic of Multidrug Resistant Tuberculosis
2007-10-24 - English

HIV Treatment and Prevention: Facing the Future
2007-10-24 - English

How to Best Sequence PI's
2007-10-25 - English

Switching from Combivir[CBV] (AZT/3TC) to Truvada [TVD] (Tenofovir DF/FTC) Maintains Viral Suppression, Prevents and Reverses Limb Fat Loss, and Improves Biochemical Parameters: Results of a 48 Week Randomised Study
2007-10-25 - English

Improvement of Survival after a Neurological AIDS Defining Event over Time
2007-10-25 - English

HIV Is My Disease
2007-10-25 - English

Prognostic Factors of Virological Success in Antiretroviral-naïve Patients Receiving LPV/r Monotherapy in the MONARK Trial
2007-10-25 - English

Should HIV Treatment Be Started Sooner?
2007-10-25 - English

Saquinavir/r (SQV/r) BID versus Lopinavir/r (LPV/r) BID, Plus Emtricitabine/Tenofovir (FTC/TDF) QD as Initial Therapy in HIV-1-infected Patients: The Gemini Study
2007-10-25 - English

HIV-Infection Increases Cystatin C Concentrations Leading to an Underestimation of Glomerular Filtration Rate
2007-10-25 - English

Frequency of Smear-positive and Drug Resistant Tuberculosis in HIV-infected atients in St. Petersburg, Russia
2007-10-25 - English

Early and Late Newly Diagnosed HIV Infections
2007-10-25 - English

Survival and Risk of Death among HIV-infected Patients who Diagnosed Cryptococcal Meningitis with/without Antiretroviral Therapy in a Resource-Limited Settings
2007-10-25 - English

Does Diabetes Mellitus (DM) Confer a Risk or Coronary Heart Disease (CHD) Equivalent to that of prior CHD in HIV-positive Individuals?
2007-10-25 - English

Which Indicator Diseases?
2007-10-25 - English

Use of Indicator Diseases to Optimize Testing
2007-10-25 - English

Terminal Differentiation of HIV-specific T Cell Responses is Restricted to Distinct Clonotypes with Low CD57 Expression
2007-10-25 - English

Influence of the Toll-like Receptor 9 1635 C/T Polymorphism on CD4 Count, HIV Viral Load and Clinical Progression
2007-10-25 - English

Protease Inhibitor Resistance Mutations Influence Recognition of Protease by HIV-1-Specific CTL
2007-10-25 - English

Antigen-specific T Lymphocytes with High Proliferative Capacity Inversely Correlate with Viral Replication in Chronically Untreated HIV-1-infected Individuals
2007-10-25 - English

Lopinavir-ritonavir Monotherapy vs Lopinavir-ritonavir and Two Nucleosides for Maintenance Therapy of HIV. Ninety-six Week Results of a Randomized, Controlled, Open Label, Clinical Trial (OK04 Study)
2007-10-25 - English

Boosted or Unboosted Atazanavir as Simplification of Lopinavir/r-containing Regimens
2007-10-25 - English

When, Why and How to Change Therapy
2007-10-25 - English

Nevirapine in Combination with Atazanavir/Ritonavir as a Nucleoside-sparing Regimen in HIV-infected-antiretroviral Experienced Subjects with Sustained Virologic Suppression (NEVATA Study)
2007-10-25 - English

Prospective HLA-B*5701 Screening Significantly Reduces the Incidence of Abacavir Hypersensitivity Reactions (ABC HSR) in Patients Treated with ABC-Containing HAART
2007-10-25 - English

Antiretroviral Changes after Viral Load Rebound in the UK Collaborative HIV Cohort (CHIC) Study
2007-10-25 - English

Triggers to Modifying Treatment
2007-10-25 - English

Trends in Transmitted Drug Resistance among Different Routes of Infection and Seroconverters as Defined by an Antibody Avidity Assay
2007-10-25 - English

Mutations Associated with Virologic Response to Darunavir/ritonavir in HIV-1-infected PI-experienced Patients
2007-10-25 - English

Transmission of HIV Drug Resistance to NNRTIs Occurs within Clusters
2007-10-25 - English

Continuation of BID Boosted PI vs Switch to Once-daily ATV/RTV for the Management of Lipodystrophy: 24-Week Interim Analysis of Metabolic and Inflammatory Parameters of the 96-Week Multicenter, Open-label, Randomised, Prospective Real Study
2007-10-25 - English

Non-alcoholic Fatty Liver Disease (NAFLD) in HIV Infected Patients: Prevalence, Characteristics and Predictors
2007-10-25 - English

Factors associated to diagnosis of NAFLD in HIV infected patients

The Pro12Ala Polymorphism of Peroxisome Proliferator Activated Receptor Gene y-2 (PPAR Gamma-2) is Associated with Increased Insulin Sensitivity in HIV-infected Patients on Antiretroviral Therapy
2007-10-25 - English

Insulin resistance in HIV infected patients on antiretroviral therapy (ART) is associated to the presence of Pro12Ala polymorphism, a common genetic variation observed in 13% of caucasian population; insulin resistance is also related to an increased weight, a prolonged ART, and also HIV/HCV coinfection.

Efficacy and Safety of Maraviroc (MVC) Plus Optimized Background Therapy (OBT) in Viraemic, Antiretroviral Treatment-Experienced Patients Infected with CCR5-Tropic (R5) HIV-1 in Europe, Australia and North America (MOTIVATE 2): 48-Week Results
2007-10-25 - English

HIV-1 Genotypic Resistance during Intermittent Antiretroviral Therapy and its Impact on CD4 Cell Counts and Antiviral Response. A Substudy of the ANRS 106 Window Trial
2007-10-25 - English

Incidence of Nevirapine-associated Hypersensitivity Reactions in Once Daily versus Twice Daily Regimen. A Collaborative Cohort Study
2007-10-25 - English

Clinical Pharmacology of the HIV Integrase Inhibitor Elvitegravir
2007-10-25 - English

Pharmacokinetics (PK) ofatazanavir/ritonavir (ATV/r) once daily (OD) and lopinavir/ritonavir (LPV/r) twice daily (BD) and ODover 72 hours following drug intake cessation
2007-10-26 - English

Pharmacokinetics (PK) of atazanavir/ritonavir (ATV/r) once daily (OD) and lopinavir/ritonavir (LPV/r) twice daily (BD) and OD over 72 hours following drug intake cessation.
Objectives: Drug persistence in plasma beyond the next due dose impacts on forgiveness around dose...(more)

Clinical Case 2 - Hepatitis C
2007-10-26 - English

Clinical Case 1 - Hepatitis B
2007-10-26 - English

Clinical Case 2 - Naive ART Patient with Marginal Increased Risk of CVD
2007-10-26 - English

Does Hepatitis C Virus (HCV) Genotype or Viral Load Predict the Risk of All-cause Mortality or HIV/HCV Coinfection?
2007-10-26 - English

Pre-exposure Prophylaxis(PrEP): State-of-the-art
2007-10-26 - English

Introduction to Hepatitis Treatment Guidelines
2007-10-26 - English

New Drugs on the Horizon for Treatment of Viral Hepatitis
2007-10-26 - English

ARTEMIS: Efficacy and safety of lopinavir (BID vs QD) and darunavir (QD) in antiretroviral-naïve patients
2007-10-26 - English

Virologic Suppression Is Maintained After Change To Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (EFV/FTC/TDF) vs. Continuation of Current Antiretroviral Therapy: Study 073 -Results of 24-week Interim Efficacy Analyses
2007-10-26 - English

Predicting the CD4 Slope in Patients Starting cART after 1st January 1999
2007-10-26 - English

Epidemiological and Virological Characteristics of Chronic Hepatitis C (HCV) within the EuroSIDA Observational Cohort
2007-10-26 - English

Growing Old with HIV
2007-10-26 - English